PuraPly® AM is a patent-protected product that is differentiated among all skin substitutes by combining a native, cross-linked collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial to ...

Introduction Poor adherence to risk factor control and life-saving medications is a key factor affecting long-term patient ...

Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial ...

A new working paper finds that preschool classrooms where teachers received an intervention designed to strengthen curriculum implementation, effective teaching practices, and teachers' engagement ...

CHANHASSEN, Minn., April 9, 2026 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in ...

MiRus today announced successful enrollment and treatment of the first patients in the STAR Trial, a prospective, multicenter ...

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...

Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...

Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...